OLR1抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane: Human placenta tissue, Primary antibody: P07993(OLR1 Antibody) at dilution 1/450, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 20 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07993(OLR1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P07993(OLR1 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The OLR1 antibody targets the oxidized low-density lipoprotein receptor 1 (OLR1), also known as LOX-1. a transmembrane glycoprotein primarily expressed on endothelial cells, macrophages, and vascular smooth muscle cells. Discovered in 1997. LOX-1 functions as a scavenger receptor that binds oxidized LDL (oxLDL), a key player in atherosclerosis. By mediating oxLDL uptake, LOX-1 contributes to endothelial dysfunction, foam cell formation, and plaque progression, linking it to cardiovascular diseases. It also interacts with other ligands, such as apoptotic cells and bacteria, implicating it in inflammation and immune responses.

OLR1 antibodies are widely used in research to study LOX-1's expression, localization, and role in pathologies like atherosclerosis, hypertension, and diabetes. Elevated LOX-1 levels are associated with oxidative stress, pro-inflammatory signaling, and endothelial injury, making it a biomarker for vascular damage. Therapeutic strategies targeting LOX-1. including neutralizing antibodies, aim to inhibit oxLDL uptake and downstream inflammatory pathways. Recent studies explore OLR1 antibodies in preclinical models to attenuate atherosclerosis and ischemia-reperfusion injury. However, clinical applications remain experimental, with ongoing research focused on optimizing specificity and delivery. Understanding LOX-1's dual roles in lipid metabolism and inflammation continues to drive interest in OLR1 antibodies as both diagnostic and therapeutic tools.